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It is now well recognized that cervical cancer is caused by infection with certain human papillomavirus (HPV) subtypes and
while interferon-a (IFN-a) is used to treat HPV-infected lesions, HPV appears to have developed a means to avoid the effects
of IFN-a. Clinically, resistance appears to be associated with the expression of the E7 oncoprotein. Here we investigated the
effects of expression in cells of the E7 protein from high- and low-risk papillomavirus subtypes on a range of responses to
IFN-a. 2fTGH, a cell line dependent on IFN-a for growth in selection medium, grew significantly less well in the presence of
E7, and the antiproliferative effects of IFN-a upon epithelial cells was lost upon E7 expression. The antiviral effects of IFN-a
were abrogated in E7-expressing cells. Loss of response to IFN-a was found to occur in both high- and low-risk papilloma-
viruses. Finally, deletion of amino acids 21–24 of HPV type 16 E7 protein partially reversed repression. We conclude that E7
inhibits the functional effects of IFN-a and that this property is shared by all HPV subtypes tested. © 2000 Academic Press
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Cervical cancer is the major cause of cancer death in
women under the age of 50 worldwide (Bosch et al.,
1995; Shah and Howley, 1996). It is now well recognized
that cervical cancer is caused by infection with certain
human papillomaviruses (IARC Working Group on the
Evaluation of Carcinogenic Risks to Humans, 1995). In-
deed, greater than 99.7% of cervical cancers contain
human papillomavirus (HPV) DNA (Walboomers et al.,
1999) and it is the first major human neoplasm for which
a single, necessary etiologic factor has been identified
(Shah, 1997). One of the major unresolved issues is that
infection with certain papillomavirus subtypes carries a
high risk for development of cancer (mainly types 16 and
18) while other subtypes are low risk (e.g., types 6 and
11). The factors that determine this risk are not fully
understood but the development of neoplasia is thought
to be associated with host genes and viral oncogenes as
well as environmental factors.
For HPV to cause cellular transformation (an extended
life span), the continued expression of the oncoproteins
E6 and E7 is required. These two proteins are known to
bind to the p53 protein and the retinoblastoma protein
(pRB), respectively (Munger et al., 1989a,b; Scheffner et
al., 1990). pRB and p53 are both tumor suppressor pro-
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411teins known to regulate cell growth via control of the cell
cycle, and loss of their function results in a finite exten-
sion of life span and bypass of the point where normal
cells would become senescent. Following this finite life
span extension, cells enter crisis and a subpopulation
may then escape to become immortal, an event associ-
ated with a second mutation. However, cells that have
become transformed and immortalized still require the
continued expression of the E6 and E7 proteins. While it
is recognized that high affinity for pRB is associated with
high-risk HPV subtypes it is a matter of conjecture that
this is the property that determines oncogenic potential,
as mutations in the pRB-binding region of E7 do not
decrease transformation ability (Jewers et al., 1992).
While interferon-a (IFN-a) is used for treatment of
enital warts, the efficacy of this treatment in terms of
irological cure is marginal, with no study having shown
ven a 50% improvement over the spontaneous recur-
ence rate, no matter what the dose or mode of delivery
Frazer and McMillan, 1997). These results raise the
ossibility that HPV has developed a mechanism to
void the effects of IFN. There is both in vivo and in vitro
vidence to support such a hypothesis. For example,
esponses to IFN-a are dramatically reduced in HPV-
transformed primary keratinocytes and cell lines while
response to IFN-g appears to be unaffected (Woodworth
et al., 1992). Furthermore, cells from lesions infected with
HPV type 16 or 18 seem to show less response to IFN-a
than those infected with HPV type 6 or 11, known as
“low-risk” HPV types (Schneider et al., 1987). Moreover,
patients who respond to IFN-a treatment have been
hown to have lower levels of E7 gene expression than
0042-6822/00 $35.00
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412 BARNARD, PAYNE, AND MCMILLANnonresponders (Arany et al., 1995a). Together these data
suggest that HPV is indeed utilizing a mechanism to
bring about the repression of the actions of IFN-a and
this mechanism could well be specific for “high-risk” HPV
types and the E7 oncoprotein.
We have recently published data that indicate that the
HPV 16 E7 protein plays a role in the downregulation of
IFN-a response due to inhibition of the signal transduc-
tion pathway (Barnard and McMillan, 1999). Type 1 IFNs
(IFN-a/b) are potent cytokines that affect a number of
ellular functions including differentiation and growth but
re recognized mainly for their antiviral activities. Loss of
ellular responses to interferon has recently been found
o occur in a number of malignancies including mela-
oma, gastric adenocarcinoma, and T-cell lymphoma
Abril et al., 1998; Sun et al., 1998; Wong et al., 1997).
Given the fact that HPV-infected lesions appear to be
resistant to IFN-a treatment, given the loss of IFN re-
sponse with some cancers, and given our previous data,
we decided to address the question of whether the E7
protein was able to functionally inhibit the actions of
IFN-a and whether any E7-mediated loss of response to
FN-a was associated with the oncogenic potential of
particular HPV types. Here we present data showing that
the expression of HPV E7 results in the loss of growth in
a cell line dependent upon IFN-a signaling for survival.
Furthermore we show that both the antiviral and the
antigrowth responses to IFN-a are lost when E7 is
resent. We also compare the inhibition by E7 among
PV types that have no cancer risk (type 1), a low risk
type 6b), and a high risk (type 16). Finally, we show that
he loss of amino acids 21–24 reduces the E7-mediated
epression of IFN-a functions.
RESULTS
PV 16 E7 inhibits IFN-a signaling activity in vivo
We have previously shown that HPV type 16 E7 (16E7)
is able to inhibit the transcription of IFN-stimulated
genes and this appears to be due to a loss of formation
of the transcription factor, interferon-stimulated gene fac-
tor 3 (ISGF3) (Barnard and McMillan, 1999). We wished to
extend these in vitro findings and investigate whether in
vivo signaling mediated by IFN-a was lost if 16E7 was
resent. Therefore we chose to use the 2fTGH cell line
eveloped by Stark, Kerr, and colleagues (see Pellegrini
t al., 1989). This cell line is dependent upon IFN-a
signaling for growth when the selection agent HAT (hy-
poxanthine/aminopterin/thymidine) is present, as the
guanine phosphoribosyltransferase (gpt) rescue gene is
driven off the IFN-a-responsive 6-16 promoter. In this
anner any perturbations of the IFN-a signaling pathway
will be manifested by a loss of cell growth. The HPV 16
E7 gene, under the control of the CMV promoter, was
introduced into 2fTGH cells and the cells were selected
with G418. Following selection the cells were pooled(2f-16E7p) and the expression of E7 was confirmed by
RT-PCR (data not shown).
The control (2fTGH) and E7-expressing (2f-16E7p) cell
lines were pretreated with 25 or 100 IU IFN-a/ml for 24 h
prior to the addition of HAT-containing medium to induce
the expression of the gpt rescue gene. Following incu-
bation for a further 24 h (the time at which maximal
repression of DNA synthesis in the absence of IFN-a
was found to occur) growth was measured using a 3-h
[3H]thymidine pulse. It can be seen that the presence of
FN-a results in a dose-dependent increase in DNA syn-
thesis in 2fTGH cells (Fig. 1). However, the expression of
the 16E7 gene resulted in a highly significant loss of
growth at both 25 and 100 IU of IFN-a/ml ( p 5 0.0009
nd 0.053, respectively), suggesting that the IFN-a signal
transduction cascade had been impaired. These data fit
well with our previous work showing that E7 perturbs the
formation of ISGF3, as ISGF3 is absolutely required for
growth of 2fTGH cells under HAT selection.
Does the level of E7 correlate with loss of IFN-a
response?
We have previously shown that E7 interacts with the
p48 protein, which is the DNA-binding component of
ISGF3. We postulate that the E7-mediated loss of IFN-a
response is caused by this interaction such that ISGF3
cannot be formed in the presence of E7. Furthermore this
binding is stoichiometric, such that a limiting amount of
E7 may not associate with all the p48 present, thus
leaving some p48 free to participate in signaling. This
hypothesis may explain, in part, the variable response of
FIG. 1. Effect of 16E7 on IFN-a-mediated signaling in vivo. Compar-
son of growth of cells (treated with 25 and 100 IU/ml IFN-a) under HAT
selection. Cells (2fTGH and 2f-16E7p) were cultured overnight in normal
medium 1 0, 25, or 100 IU/ml IFN-a before the addition of HAT
selection medium 1 IFN-a for 24 h. Cell growth, dependent on the 6-16
promoter driving the gpt rescue gene, was assayed by [3H]thymidine
incorporation.papillomavirus infections to IFN-a treatment.
To test this we decided to take advantage of our 2fTGH
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413E7 INHIBITS THE FUNCTIONS OF IFN-asystem by creating a number of clonal cell lines with
variable levels of HPV 16E7 expression. Five E7-express-
ing clonal cell lines were generated and the level of E7
mRNA was measured using real-time (TaqMan) PCR and
corrected against the b-actin level of each cell line. As
ittle as 250 copies of E7 mRNA could be detected using
eal-time PCR (data not presented). It was observed that
ach cell line had a variable level of E7 expression (Fig.
A). The 2f-16E7-2 cell line had the highest level of
xpression (1.23 3 105 copies/20 ng total RNA input)
hile cell line 2f-16E7-1 had the lowest (0.46 3 105
copies/20 ng total RNA input).
These cell lines were assayed for their ability to grow
under HAT selection in the presence of 25 IU IFN-a/ml
and the results are presented as fold-induction (Fig. 2A).
Control 2f-neo cells gave a maximal response while U2A
cells (a 2fTGH-based cell line lacking functional p48 and
therefore unresponsive to IFN-a) were unable to re-
spond. It can be seen that high levels of E7 correlated to
low response to IFN-a (cell line 2) while cell lines with a
ow level of E7 expression had normal responses (cell
ine 1). Analysis of these data by linear regression indi-
ates a significant trend ( p 5 0.0062) (Fig. 2B) whereby
FIG. 2. Effect of the level of 16E7 on IFN-a-mediated signaling. (A)
ells (2f-16E7 clonal cell lines, 2f-neo, and U2A) were treated overnight
ith 25 IU/ml IFN-a in normal medium followed by 24 h with 0 or 25
U/ml IFN-a in HAT selection medium. Cell growth, dependent on the
-16 promoter driving the gpt rescue gene, was assayed by [3H]thymi-
ine incorporation. The level of 16E7 mRNA in each clonal cell line was
stimated using TaqMan probes and real-time PCR. Levels were cor-
ected against b-actin. (B) Analysis of data by linear regression.ncreasing levels of 16E7 result in increasing inhibition of
he IFN-a signaling. 37 inhibits the antiproliferative activities of IFN-a
HPV does not normally infect or grow in fibroblasts
such as 2fTGH. Furthermore 2fTGH cells have been
genetically altered to be dependent upon IFN-a signal-
ing, by virtue of the expression of the gpt rescue gene,
and are not sensitive to the antiproliferative effects of
IFN-a. Therefore, the antiproliferative properties of IFN-a
due to the expression of IFN-stimulated genes are not
directly addressed in the 2fTGH system. Therefore we
expressed the HPV 16 E7 gene in a human epithelial cell
line, HaCaT, and measured growth response using the
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bro-
mide (MTT) assay (Denizot and Lang, 1986). HaCaT-E7
cells were generated by transfection with pcDNA3-16E7
and following selection in G418, cells were pooled and
expression of E7 mRNA was confirmed by RT-PCR (data
not shown). Cells were treated with varying amounts of
IFN-a for 2 days and growth was assessed. The growth
of cells transfected with vector alone (HaCaT-neo) was
inhibited by treatment with as little as 10 IU/ml of IFN-a
and was further reduced by increasing doses (Fig. 3).
However, cells expressing E7 were not suppressed by
IFN-a treatments up to 100 IU/ml, indicating that these
cells can proliferate normally in the presence of IFN-a.
This was not due to any spurious effect of E7 upon
HaCaT cell growth as both control and 16E7-expressing
cell lines had the same growth kinetics over time in the
absence of IFN-a treatment (data not shown).
E7 inhibits the antiviral activities of IFN-a
We have previously shown that the presence of 16E7
results in the loss of induction of PKR mRNA upon IFN-a
treatment (Barnard and McMillan, 1999). PKR has a ma-
jor role in the antiviral activity of IFN-a. Therefore we next
investigated the effect of 16E7 expression on the antiviral
activity of IFN-a. As it has previously been shown that
2fTGH cells can be infected with Semliki Forest virus
(SFV) (Pellegrini et al., 1989), we tested the resistance of
FIG. 3. Effect of E7 on IFN-a-mediated antiproliferative activity. Cells
(HaCaT-neo and HaCaT-16E7) were serum-starved for 3 days and then
treated with 0–100 IU/ml IFN-a in serum-free medium for 2 days at
7°C. Cell growth was assessed daily by MTT assay.
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414 BARNARD, PAYNE, AND MCMILLANthe 2fTGH cell lines expressing 16E7 to SFV infection in
the presence of IFN-a. Preliminary data indicated that
otal protection (as measured by CPE) was attained by
00 IU/ml of IFN-a at a multiplicity of infection (m.o.i.) of
.002 (data not shown). The assay chosen to investigate
he role of E7 was the same as that used by Leonard and
en (1997) to investigate adenovirus E1A inhibition of
FN-a antiviral response—the viral reduction assay. The
rinciple of this assay is that cells pretreated with IFN-a
inhibit viral replication and therefore fewer viral progeny
are produced than in untreated cells. This can be ex-
pressed as a fold-reduction in virus yield. Any perturba-
tion in IFN-a signaling will reduce the antiviral effect,
llowing virus replication to occur more readily in IFN-
a-treated cells, thereby giving a lower fold-reduction.
We initially tested the antiviral activities in two 16E7-
expressing cell lines, 2f-16E7-2 (high E7 levels) and 2f-
16E7-1 (low E7 levels). First, we investigated the yield of
SFV in untreated cell lines to ensure that each cell line
was fully competent for viral replication. Cells were in-
fected with SFV (m.o.i. 5 0.002) for 48 h before virus was
harvested and enumerated in a plaque assay using Vero
cells. It can be seen that there were no significant dif-
ferences in the yield of virus from control and E7-ex-
pressing cells, suggesting that the presence of E7 did
not affect the production of virus in untreated cells
(Fig. 4A).
Next we pretreated cells 6IFN-a (100 IU/ml) overnight
before infecting them with SFV as above. Virus was
harvested and counted in plaque assays and the fold-
reductions were calculated. Fold-reductions of 5600 and
4400 were observed for 2fTGH and 2f-neo cells, respec-
tively, indicating that the IFN-a-mediated antiviral re-
ponse was functional in these cells (Fig. 4B). As ex-
ected, the U2A cell line (a 2fTGH-based cell line lacking
unctional p48 and therefore unresponsive to IFN-a) had
nly a 2-fold reduction in virus yield. Interestingly, 2f-
6E7-2 cells (high E7) also had a low fold-reduction (6.3),
ndicating that there was a loss of antiviral activity in
hese cells, whereas 2f-16E7-1 cells (low E7) had an
ntermediate fold-reduction (1042). Cell lines with inter-
ediate levels of E7 (2f-16E7-7 and -14) gave intermedi-
te fold-reductions (78 and 20, respectively). These re-
ults suggest that 16E7 is able to inhibit the antiviral
ctivity of IFN-a and that higher levels of 16E7 give better
inhibition. These data are consistent with the 2fTGH
growth data above and our previous observations that
PKR mRNA induction is lost in 16E7-expressing cells.
However, the antiviral assay appeared to be more sen-
sitive to the level of 16E7 than the antigrowth assay.
What region of E7 is involved?
The E7 protein has a number of known functional
domains including conserved region 2 (CR2), which con-
tains the consensus pRB-binding domain (LXCXE) andthe casein kinase II phosphorylation sites. However,
other regions remain largely undefined in terms of func-
tion, including CR1 (amino acids 1–15). As our previous
work had shown that a peptide representing the region
17–37 specifically interacted with p48, we decided to use
two well-defined deletion mutants of 16E7, D6-10
(PTLHE) and D21-24 (DLYC), to address the issue of
which region of 16E7 was involved in suppressing IFN-a
function. These mutants were chosen as they contained
deletions in the undefined CR1 domain and the CR2
domain known to interact with p48. The mutant E7 genes
were cloned into the expression plasmid pcDNA3neo,
and stable clonal cell lines were generated. The level of
mRNA expression was determined by real-time PCR
analysis and the cell lines with expression levels match-
ing the highest wild-type 16E7-expressing cell line (2f-
16E7-2) were chosen for further analysis.
The mutants were tested for their ability to interfere
with the antiviral activities of IFN-a in the virus reduction
assay. As before, the virus yield from untreated cells was
determined to ensure that each cell line was fully com-
petent for virus replication (data not shown). Interest-
FIG. 4. Comparison of IFN-a-mediated antiviral activity in 16E7-
expressing cell lines. Cells were pretreated with 0 or 100 IU/ml IFN-a
overnight before infection with Semliki Forest virus (m.o.i. 5 0.002).
After 48 h, virus yield was assessed by plaque assay using Vero cells.
(A) Comparison of SFV yield from untreated 2fTGH, 2f-neo, U2A, and
16E7-expressing clonal cell lines 2f-16E7-1 and 2f-16E7-2. (B) Compar-
ison of the fold-reduction in SFV yield due to treatment with IFN-a.ingly, the D21-24 mutant had an increased viral reduction
(110-fold) compared to wild-type E7 (8.2-fold) and the
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415E7 INHIBITS THE FUNCTIONS OF IFN-aD6-10 mutant (7.3-fold), suggesting that the loss of amino
acids 21–24 partially impaired the ability of E7 to inhibit
IFN-a activity (Fig. 5).
s inhibition associated with oncogenic ability?
Finally, we wished to address the question of the role
f the E7-mediated loss of IFN-a activity and how this
may relate to the oncogenic potential of particular HPV
subtypes. It has been shown that cells from lesions
containing HPV type 16 or 18 appear to be less respon-
sive to IFN-a than those infected with type 6 or 11
(Schneider et al., 1987). Conversely, patients who re-
spond to IFN-a treatment have lower levels of 16E7 gene
expression (Arany et al., 1995b). In order to answer this
uestion we decided to clone the E7 genes from HPV
ypes 6b (low cancer risk) and 1 (no risk) and investigate
heir ability to inhibit IFN-a responses in the antiviral
ssay. In this way we hoped to ascertain the nature of the
ajor determining factor in inhibition—the HPV subtype
r the level of E7 in the cell.
As before, stable, clonal cell lines expressing either
bE7 or 1E7 were made and the level of E7 mRNA was
stimated by real-time PCR and corrected against the
evel of human b-actin (also determined by real-time
CR). In this way the level of E7 mRNA could be com-
ared between cell lines and E7 types. The cell lines
rom each subtype with the highest expression levels
ere chosen for analysis in the antiviral fold-reduction
ssay. It can be seen that the expression of both 1E7 and
bE7 was able to significantly inhibit the antiviral re-
ponse to IFN-a in 2fTGH cells in a manner similar to
16E7 (Fig. 6). This result indicates that the E7-mediated
inhibition of IFN-a response does not correlate with
ncogenic potential but rather appears to be a general
eature of all papillomaviruses. Interestingly, the mRNA
evels of 6bE7 and 1E7 (4122 and 6555 copies/20 ng total
NA input, respectively) were much lower than that of
FIG. 5. Antiviral effects of 16E7 mutants. Stable cell lines expressing
wild-type 16E7 or the 16E7 mutants D6-10 (PTLHE) and D21-24 (DLYC)
were pretreated with 0 or 100 IU/ml IFN-a overnight before infection
with Semliki Forest virus (m.o.i. 5 0.002). After 48 h, virus yield was
assessed by plaque assay using Vero cells and data are presented as
fold-reductions in virus yield.6E7 (123,617 copies/20 ng total RNA input), yet both
ere as effective in inhibiting IFN-a responses.DISCUSSION
The work presented here extends our previous data
nd shows for the first time that the expression of the
uman papillomavirus E7 protein is able to inhibit the
unction of IFN-a. This was shown to occur for both the
antiproliferative and the antiviral properties of IFN-a.
Furthermore, IFN-a-mediated signaling in vivo was
shown to be repressed as 2fTGH cells under HAT selec-
tion were unable to grow in the presence of 16E7. Inhi-
bition with the antiviral assays was more pronounced,
perhaps reflecting the fact that the antiviral effect of
IFN-a is the product of a limited number of genes that
ave very direct and potent activities, whereas the anti-
roliferative effects are somewhat more complex and not
imited to direct effects. Nevertheless, similar trends
ere observed in that higher levels of E7 gave higher
evels of inhibition. These results may therefore explain
he variable clinical responses to IFN-a treatment of
PV-infected lesions. Lesions with higher levels of E7
ould be predicted to be more resistant to the effects of
FN-a than those with lower levels and there is clinical
evidence to support this hypothesis. Arany et al. (1995b)
have shown that patients who respond to IFN-a treat-
ment do indeed have lower levels of E7 than nonre-
sponders.
Our data also show that there is no relationship be-
tween the oncogenic ability of a particular HPV subtype
and its ability to downregulate IFN-a responses via E7.
his is evidenced by the loss of the antiviral responses in
ype 16, 6b, and 1 E7-expressing cells (Fig. 6). This would
uggest that the ability to regulate IFN-a responses may
be a general property of all papillomaviruses. However,
type 11 E7 has been reported to be unable to do this (see
below) and therefore this conclusion remains to be
proven. An interesting observation from these data was
that while each subtype was equally as effective at
inhibiting the IFN-a response, the levels of E7 mRNA
rom types 1 and 6b were 10- to 20-fold lower than that
rom type 16. For these assays the cell line that ex-
ressed the highest level of E7 for each type was cho-
en. This result may be explained in a number of differ-
FIG. 6. Comparison of HPV type 1, 6b, and 16E7 expression on the
functions of IFN-a. Analysis of the antiviral activity by fold-reduction in
virus yield due to IFN-a treatment of cells.
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416 BARNARD, PAYNE, AND MCMILLANent ways. It may indeed be true that lower cancer risk
HPV subtypes are more potent inhibitors of IFN-a re-
ponses than higher risk types. However, this relies
pon the assumption that the level of mRNA translates
irectly to protein level. Perhaps types 1 and 6b E7
rotein is much more stable than that of type 16, there-
ore leading to better inhibition. There are no published
ata on the stability of E7 protein, other than type 16,
hich was found to have a half-life of 37 min at 22°C
Selvey et al., 1992), and until such data are known for
ther types no meaningful conclusions can be drawn.
nother potential explanation why types 1 and 6b were
ore effective at inhibiting the IFN-a response is that a
ajor function of E7 is to maintain cellular growth, per-
aps in part by preventing the antiproliferative effects of
FN. If 1E7 and 6bE7 are more potent inhibitors, one
ight therefore expect lesions containing these viruses
o be larger than those caused by type 16, and indeed
his is the clinical observation. Plantar and genital warts,
he result of HPV type 1 and 6b/11 infection, respectively,
re much larger and more proliferative than lesions
aused by HPV type 16 and this may be in part due to the
ffective loss of IFN-a responses. Finally, it may be that
he level of E7 mRNA itself is the most important factor in
ncogenesis, a matter that would require a detailed
linical investigation.
We observed that deletion of amino acids 21–24
DLYC) from 16E7 resulted in a partial loss of the ability
o inhibit IFN-a responses. This confirms our previous
data showing that the region encompassing amino acids
17–37 is the region involved in p48 binding. These amino
acids form part of the CR2 domain that has been shown
to be involved in binding to pRB (Barbosa et al., 1990;
Dyson et al., 1992). This suggests a number of possibil-
ities, including p48 binding directly to amino acids 21–24,
p48 binding via an interaction with pRB or other pocket
proteins, or mutation of the region changing the confor-
mation of E7 such that E7 is no longer stable, functional,
or able to bind p48. In this respect E7 appears to act
differently than E1A as deletion of the E1A CR2 domain
has no effect on IFN-a repression (Gutch and Reich,
991; Kalvakolanu et al., 1991). The region within E1A
hown to be involved in IFN-a repression lies in the CR1
omain, equivalent to the first 15 amino acids of E7.
owever, it is known that E1A requires both the CR1 and
he CR2 domains in order to bind pRB, whereas E7
equires only CR2, so it remains possible that repression
f the IFN-a response may still involve pRB for both E1A
nd E7.
Papillomaviruses appear to have developed a remark-
ble number of mechanisms to avoid the effects of IFN-a
given their limited number of genes. Chiefly, these seem
to involve two genes—E6 and E7. HPV E6 has been
shown to interact with the kinase Tyk2 in a fashion that
limits its interaction with the IFN receptor and conse-
quently impairs JAK-STAT activation (Li et al., 1999). This
i
Tfunction is found in type 18 E6 but not type 11, suggesting
that this is a property of a high-risk oncogenic HPV.
However, HPV 11 may represent a unique case as it
appears to be sensitive to IFN-a, whereas HPV type 6,
genetically a very close relative, is not (Garcia-Millian et
al., 1999). E6 has also been shown to bind to IRF3, a
transcription factor implicated in the regulation of the
IFN-a/b gene induction. Interestingly, type 16 E6 bound
much better to IRF3 than type 18 E6, suggesting that this
is not associated with the oncogenic phenotype. E7 has
recently been found to bind to IRF1, a transcription factor
involved in regulation of a subset of IFN-a-regulated
enes (Park et al., 2000). However, IRF1 is itself induced
y IFN-a, presumably via ISGF3, and is therefore down-
stream of any effects involving p48.
The loss of IFN-a responses in papillomavirus E7-
xpressing cells has recently been reported by Garcia-
illian et al. (1999), who found that HPV 6 and 16 E7 were
able to inhibit IFN responses, whereas HPV 11 E7 could
not. As noted above, type 11 E6 is reported to be unable
to interact with Tyk2, indicating that HPV type 11 has a
number of defects in interferon-suppressive pathways.
This suggests that type 11 has developed other, as yet
unknown, mechanisms to avoid the effects of IFN-a.
The major problem with HPV infection is that while
there are treatments available, mostly destructive in na-
ture, all are cosmetic and none are effective in terms of
a virological cure. IFN-a as a treatment has been mar-
ginally successful but as with many other viral diseases
treated with IFN-a, there is a high proportion of nonre-
sponders and partial responders. Our work shows that
the presence of E7 inhibits responses to IFN-a and that
higher levels of E7 result in more inhibition. This may
explain, in part, the variable clinical responses to IFN-a
treatment and by using these data it may be possible to
predict response to IFN-a therapy by measuring the level
f E7.
MATERIALS AND METHODS
lasmids and cell lines
pcDNA3-16E7 was created by excising the 16E7 gene
rom pCMV16E7 using HindIII/EcoRI and cloning it into
he HindIII/EcoRI sites of pCDNA3 (InVitrogen, Carlsbad,
A). pcDNA3-6bE7 was cloned by excising the 6bE7
ene from pGEM4Z-6bE7/4a-1 (a gift from Professor Ian
razer, University of Queensland, Brisbane, Australia),
sing a HindIII/EcoRI digest, and cloning as above.
cDNA3-16E7D21-24 (DLYC) and pcDNA3-16E7D6-10
PTLHE) constructs were a gift from Peter Manders (Uni-
ersity of Queensland, Brisbane, Australia) and were
repared from PCR products amplified from recombinant
etrovirus expression constructs from Dr. Denise Gallo-
ay (Seattle, WA). pcDNA3-1E7 was prepared by excis-ng the 1E7 gene from pBABEpuro-1E7 (a gift from Dr.
ommasino, DKFZ, Heidelberg, Germany) with BamHI/
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417E7 INHIBITS THE FUNCTIONS OF IFN-aSalI and cloning into the vector pBS (SK2) before excis-
ng 1E7 from pBS (SK2) with BamHI/XhoI and cloning into
pcDNA3.
The 2fTGH cell line, a human diploid fibroblast cell line
stably transfected to express guanine phosphoribosyl-
transferase under the control of the 6-16 gene 59 untrans-
ated region (Pellegrini et al., 1989), and U2A cells (mu-
ated 2fTGH cells, p48/ISGF-3g-negative) (John et al.,
991) were a generous gift from Dr. George Stark (Cleve-
and Clinic Foundation, Cleveland, OH). HaCaT cells
ere a gift from Dr. Nobert Fusening (Deutsches
rebsforschungszentrum, Heidelburg, Germany).
All cell lines were cultured in Dulbecco’s modified
agle’s medium (DMEM) supplemented with 10% fetal
alf serum. 2fTGH and U2A cell lines were cultured in the
resence of 250 mg/ml hygromycin B to maintain selec-
tion of stably transfected cells.
Transfection of cells
Cells were transfected with 10 mg of pcDNA3neo con-
taining the E7 gene using DOTAP transfection reagent
(Roche Molecular Biomedicals, Sydney, Australia).
Briefly, DNA was combined with 25 ml DOTAP transfec-
ion reagent in 20 mM HEPES buffer, pH 7.4, to a final
olume of 150 ml and incubated at room temperature for
10 min. The DNA:DOTAP mixture was combined with 6
ml of DMEM/10% FCS and added to an 80% confluent
T-75 flask of 2fTGH cells (which had been removed from
hygromycin B selection for 48 h) or HaCaT cells and
incubated for 8 h at 37°C. The medium was replaced
with fresh DMEM/10% FCS and cells were incubated for
a further 48 h at 37°C. Following this, cells were selected
with 500 mg/ml G418 (Roche Molecular Biomedicals)
until colonies of stably transfected cells formed (2–3
weeks). At this stage transfected cells were pooled or
clonal cell lines were established from individual colo-
nies. All transfected cells were cultured in 500 mg/ml
G418 to maintain selection.
2fTGH survival assay
2fTGH, U2A, and stable transfectants of 2fTGH cells
were grown to confluency in DMEM/10% FCS medium
(selection was removed one passage prior to experi-
ment). Cells were trypsinized and 20,000 cells were
seeded into a 6-well plate in 2 ml DMEM/10% FCS
medium. All treatments were performed in triplicate. Af-
ter incubation at 37°C for 24 h, the medium was changed
to DMEM/10% FCS 6 25 IU/ml IFN-a, and incubation
continued for 24 h at 37°C. Medium was changed to HAT
selection medium (DMEM/10% FCS plus 100 mM hypo-
xanthine, 40 mM aminopterin, and 1.6 mM thymidine) 6
25 IU/ml IFN-a. Cells were incubated at 37°C for 21 h
before the addition of 10 mCi of [3H]thymidine to each
well and incubation continued for 3 h at 37°C. Following
this cells were washed three times in ice-cold PBS and
p
wfixed in an ice-cold solution of 10% acetic acid:90% eth-
anol for 30 min. Cells were washed three times in ice-
cold PBS and lysed in 600 ml of 0.5 M NaOH at 37°C for
0 min before the solution was neutralized with 600 ml of
M HCl. The level of [3H]thymidine was analyzed in a
Packard Tri-Carb 2700TR liquid scintillation analyzer.
Readings were expressed as fold-growth, this being the
ratio of DNA synthesis in cells treated with IFN-a to that
in untreated cells.
MTT assay
HaCaT-based stable transfectants were seeded into
96-well plates (4500 cells/well) and cultured for 24 h at
37°C before being serum-starved in serum-free DMEM
for 3 days at 37°C. Cells were then cultured in DMEM/
10% FCS medium supplemented with 0–100 IU/ml IFN-a
for up to 2 days at 37°C. Cells were washed in 13 PBS,
and then 150 ml of 13 PBS was added to each well of
ells. Fifty microliters of a 2 mg/ml MTT (Sigma Aldrich,
Sydney, Australia) solution (prepared just prior to addi-
tion) was added to each well, and cells were incubated
at 37°C for 3 h. MTT stain was removed from cells, and
the cells were lysed in 150 ml dimethyl sulfoxide (Sigma
Aldrich). Absorbance was read at a wavelength of
595 nm.
Real-time PCR analysis
Total cell RNA was extracted using Trizol reagent as
per the manufacturer’s instructions (Life Technologies,
Australia). cDNA was synthesized from 2 mg of total RNA
sing Omniscript (Qiagen, Sydney, Australia) according
o the manufacturer’s instructions. cDNA (50 ng) was
dded to 12.5 ml TaqMan Universal PCR master mix,
orward and reverse primers (300 nM final concentra-
ion), TaqMan probe (200 nM final concentration), and
ater to a final volume of 25 ml. This was analyzed in an
ABI Prism 7700 Sequence Detector under the following
PCR conditions: 40 cycles of 15 s at 95°C and 1 min at
60°C with sampling of fluorescence after each cycle as
recommended by the manufacturer (PE Applied Biosys-
tems, Melbourne, Australia). Copy number was deter-
mined by measuring the C T value and comparing this to
standard curve and correcting against the value for
b-actin according to the manufacturer’s instructions (PE
Biosystems ABI 7700 User Bulletin 2). The probe used for
detection of 16E7 was as described by Frazer et al.
(manuscript in preparation). For detection of 6b E7, for-
ward primer 59-AGTGACCTGTTGCTGTGGATGT-39; re-
verse primer 59-GCACTTCTCTGATGTCTGTTTCTGTAC-
39, and probe 6FAM-TGCACAACCAGTCGAACGTT-
CTGT-TAMRA were used, and for detection of type 1E7,
orward primer 59-CTGTGCCTATTGCGAGAAACTG-39, re-
erse primer 59-GCTGTCTAATGGCGCTGTGA-39, and
robe 6FAM-TTCGATTGACCGTCCTCGCGG-TAMRA
ere used.
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418 BARNARD, PAYNE, AND MCMILLANAntiviral assay
Cells (20,000) were seeded into 6-well plates and
incubated at 37°C for 48 h. Medium was changed to
DMEM/10% FCS 6 100 IU/ml IFN-a and cells were in-
ubated for 18 h at 37°C. Cells were infected at an m.o.i.
f 0.002 in serum-free DMEM and incubated at 37°C for
h before being washed in 13 PBS, DMEM/10% FCS
edium was added, and incubation continued at 37°C
ntil CPE was observed (48 h). Virus was released by
hree cycles of freeze/thawing and virus concentration
as estimated by plaque assay using Vero cells as
ollows. Unknown virus supernatants were serially di-
uted (1022 to 1028) in serum-free DMEM and placed onto
ero cells (95% confluent) for 1 h at 37°C. Cells were
ashed and covered with agar (3% agar autoclaved in
ank’s balanced salt solution mixed 1:3 with DMEM/10%
CS) before incubation at 37°C for 48 h. Neutral red
olution (0.033%) was placed on agar overlays, which
ere then incubated overnight at 37°C. They were then
rained and plaques were counted.
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